Living with SJS/TEN
Advocacy
SJS/TEN is rare enough that many clinicians will see one case in a career. That places an unreasonable but real burden on survivors to advocate — for themselves, and for the people who come after.
Report the reaction. It counts.
Drug safety labelling changes because reactions get reported. If your reaction has not been reported to the national system, it can be — by you, not only by a clinician.
- FDA MedWatch — report a serious adverse event ↗
The US voluntary reporting route, open to patients and carers as well as clinicians. Reports feed directly into safety labelling decisions.
- VAERS — for reactions following vaccination ↗
The separate US system for vaccine adverse events, run jointly by the CDC and FDA.
Advocating inside your own care
The recurring failures survivors describe are not exotic. They are ordinary gaps: the eyes not examined during the admission, the trigger drug not recorded as an allergy, nobody mentioning that genital involvement is common until scarring has set in, follow-up that stops when the skin heals.
Concrete things that help:
- Ask for an ophthalmology consult during the acute admission, not after. If you are reading this on behalf of someone currently admitted, this is the single most useful sentence on this page.
- Check that the trigger drug is entered as an allergy in every system that holds your records, not written in a discharge summary nobody reopens.
- Ask for the diagnosis in writing, with the date and the drug. You will need it repeatedly, often years later.
- Take someone with you to appointments where you expect to be told something complicated. Two people remember more than one.
Awareness
Patient organisations run awareness campaigns, and they are more effective with survivor voices attached. If you are willing to tell your story publicly, the SJS Foundation and SJS Awareness UK both do this. If you are not willing, that is entirely reasonable — there are quieter ways to contribute, including taking part in research.